Uscom LimitedLevel 7, 8-10 Loftus Street Sydney NSW 2000...

Uscom Limited
Level 7, 8-10 Loftus Street Sydney NSW 2000 Australia
Phone: 61-2-9247 4144 Fax: 61-2-9247 8157
ABN: 35 091 028 090
www.uscom.com.au

MARKET ANNOUNCEMENT
UNIT SALES UPDATE
· 9 USCOM 1A devices to Asia
· 30 USCOM 1A devices order from Spacelabs Healthcare

Thursday, 22 January 2009: Uscom (ASX Code: UCM) today informed shareholders of the receipt of orders for 39 units in January. Orders were received from Pacific Medical Systems for 9 units,8 units for China and 1 for their new market in Indonesia.
Spacelabs Healthcare placed an order for 30 units to support their launch of the USCOM in the USA at the Society of Critical Care Medicine on February 1, 2009. All of the units are to be delivered in January and will be branded Spacelabs Healthcare.

Uscom CEO, Mr. Paul Butler said “It is encouraging to start the new year off on such a positive note. The initial order from Spacelabs is part of their ramp up and I look forward to receiving many more as their sales team progressively and more actively promote the USCOM product to their customers.

I am pleased for the team at Pacific Medical Systems who are yielding the results of their efforts with multiple unit orders starting to come through from China and also their work in opening up new markets such as Indonesia.”

Mr Rob Phillips, Executive Chairman and Director of clinical Science said “This order from Spacelabs Healthcare is the first from the new marketing relationship in the USA. We are anticipating that through their extensive marketing infrastructure they will be able to leverage our increasingly strong scientific position and achieve significant sales.”

About Uscom
Uscom Limited (UCM) is an Australian medical device company, listed on the Australian Stock Exchange since December 2003. Uscom has developed a non-invasive device for the safe and accurate measurement of cardiac output, as an alternative to the current invasive methods. The device provides real-time beat-to-beat information across multiple parameters of cardiac function and provides advanced trending capabilities, allowing clinicians to accurately quantify the effect of treatment. The device is ideally suited to Paediatrics, Intensive Care and Emergency Medicine, and Anaesthesia where it is critical to monitor changes in cardiac output as fluids and drugs are administered.

Uscom holds a number of national and international patents and patent applications predominantly related to cardiovascular assessment.
The Company has secured regulatory approval for sale of the USCOM 1A Monitor in Australia, Europe and a number of Asian markets, including Japan, China and Taiwan. Uscom also has a CE Mark certification for Europe and a license from the State Food & Drug Administration for China.
The Company received the necessary regulatory clearance for the United States market in February 2005 with the receipt of a 510K Pre Market Notification from the US Food & Drug Administration (FDA).